<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">microbe</journal-id><journal-title-group><journal-title xml:lang="ru">Проблемы особо опасных инфекций</journal-title><trans-title-group xml:lang="en"><trans-title>Problems of Particularly Dangerous Infections</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">0370-1069</issn><issn pub-type="epub">2658-719X</issn><publisher><publisher-name>Russian Research Anti-Plague Institute “Microbe”</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21055/0370-1069-2020-4-47-52</article-id><article-id custom-type="elpub" pub-id-type="custom">microbe-1403</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>Получение рекомбинантных антигенов для проведения серологической диагностики лихорадки Марбург</article-title><trans-title-group xml:lang="en"><trans-title>Obtaining Recombinant Antigens for the Development of Serological Diagnosis of Marburg Fever</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5010-9424</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Волкова</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Volkova</surname><given-names>N. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>630559, Новосибирская обл., п. Кольцово</p></bio><bio xml:lang="en"><p>Kol’tsovo, Novosibirsk Region, 630559</p></bio><email xlink:type="simple">vector@vector.nsc.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9102-6756</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Иванова</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Ivanova</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>630559, Новосибирская обл., п. Кольцово</p></bio><bio xml:lang="en"><p>Kol’tsovo, Novosibirsk Region, 630559</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4085-2887</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Исаева</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Isaeva</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>630559, Новосибирская обл., п. Кольцово</p></bio><bio xml:lang="en"><p>Kol’tsovo, Novosibirsk Region, 630559</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4256-5064</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Полежаева</surname><given-names>О. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Polezhaeva</surname><given-names>O. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>630559, Новосибирская обл., п. Кольцово</p></bio><bio xml:lang="en"><p>Kol’tsovo, Novosibirsk Region, 630559</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0450-5212</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Зайковская</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Zaykovskaya</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>630559, Новосибирская обл., п. Кольцово</p></bio><bio xml:lang="en"><p>Kol’tsovo, Novosibirsk Region, 630559</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8023-4453</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Щербаков</surname><given-names>Д. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Shcherbakov</surname><given-names>D. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>630559, Новосибирская обл., п. Кольцово</p></bio><bio xml:lang="en"><p>Kol’tsovo, Novosibirsk Region, 630559</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1856-6147</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Казачинская</surname><given-names>Е. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Kazachinskaya</surname><given-names>E. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>630559, Новосибирская обл., п. Кольцово</p></bio><bio xml:lang="en"><p>Kol’tsovo, Novosibirsk Region, 630559</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФБУН «Государственный научный центр вирусологии и биотехнологии «Вектор»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>State Scientific Centre of Virology and Biotechnology “Vector”</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>04</day><month>02</month><year>2021</year></pub-date><volume>0</volume><issue>4</issue><fpage>47</fpage><lpage>52</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Волкова Н.В., Иванова А.В., Исаева А.А., Полежаева О.А., Зайковская А.В., Щербаков Д.Н., Казачинская Е.И., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Волкова Н.В., Иванова А.В., Исаева А.А., Полежаева О.А., Зайковская А.В., Щербаков Д.Н., Казачинская Е.И.</copyright-holder><copyright-holder xml:lang="en">Volkova N.V., Ivanova A.V., Isaeva A.A., Polezhaeva O.A., Zaykovskaya A.V., Shcherbakov D.N., Kazachinskaya E.I.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://journal.microbe.ru/jour/article/view/1403">https://journal.microbe.ru/jour/article/view/1403</self-uri><abstract><p>Цель работы – получение рекомбинантных вирусных антигенов основных иммунодоминантных белков: гликопротеина (GPΔMLD), нуклеопротеина (NP) и матриксного белка (VP40) вируса Марбург, а также исследование их антигенных и иммуногенных свойств.</p><sec><title>Материалы и методы</title><p>Материалы и методы. Для создания рекомбинантных белков GPΔMLD, NP и VP40 вируса Марбург использовали синтезированные нуклеотидные последовательности, кодирующие эти белки, клонированные в составе экспрессионного вектора pЕТ21a. Иммуногенные и антигенные свойства полученных рекомбинантных белков проверяли с использованием ряда биомоделей (мыши, куры и морские свинки).</p></sec><sec><title>Результаты и обсуждение</title><p>Результаты и обсуждение. Получены рекомбинантные плазмиды, содержащие гены, кодирующие белки GPΔMLD, NP, VP40 вируса Марбург, а также штаммы-продуценты Escherichia coli, с выходом очищенных препаратов рекомбинантных белков GPΔMLD, NP, VP40 с одного литра культуральной жидкости – 5, 10 и 10 мкг соответственно. Рекомбинантные белки GP, NP и VP40 MARV при иммунизации мышей вызывают синтез антител с высоким титром (рекомбинантные белки NP и VP40 – более 409600, а рекомбинантный белок GPΔMLD – 12800). Мышиные антитела, специфичные к рекомбинантным белкам, взаимодействуют в иммуноферментном анализе с антигеном инактивированного MARV. Антитела кур, иммунизированных вирусоподобными частицами, содержащими на поверхности поверхностный гликопротеин вируса Марбург, и антитела морских свинок, иммунизированных экспериментальной ДНК-вакциной, содержащей ген GPΔMLD MARV, узнают рекомбинантный белок GPΔMLD и вирусный белок в составе инактивированного MARV. Полученные рекомбинантные белки обладают иммуногенностью/антигенностью и могут использоваться для разработки иммуноферментных тест-систем. </p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim. Production of recombinant viral antigens of the main immunodominant proteins: glycoprotein (GPΔMLD), nucleoprotein (NP) and matrix protein (VP40) of the Marburg virus, as well as the study of their antigenic and immunogenic properties.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. To create recombinant proteins GPΔMLD, NP and VP40 of the Marburg virus, synthesized nucleotide sequences encoding these proteins cloned into the pET21a expression vector were used. The immunogenic and antigenic properties of the obtained recombinant proteins were tested using a number of biomodels (mice, chickens, and guinea pigs).</p></sec><sec><title>Results and discussion</title><p>Results and discussion. Recombinant plasmids containing genes encoding proteins GPΔMLD, NP, VP40 of the Marburg virus, as well as Escherichia coli producing strains, with the yield of purified preparations of recombinant proteins GPΔMLD, NP, VP40 from one liter of culture fluid – 5, 10, and 10 μg were obtained, respectively. When mice are immunized, recombinant proteins GP, NP, and VP40 MARV induce the synthesis of high titer antibodies (recombinant proteins NP and VP40 – more than 409600, and recombinant protein GPΔMLD – 12800). Mouse antibodies specific to recombinant proteins interact in an enzyme-linked immunosorbent assay (ELISA) with the antigen of inactivated MARV. Antibodies of chickens immunized with virus-like particles containing the surface glycoprotein of the Marburg virus and antibodies of guinea pigs immunized with an experimental DNA vaccine containing the GPΔMLD MARV gene recognize the recombinant GPΔMLD protein and the viral protein in the inactivated MARV. The resulting recombinant proteins are immunogenic/antigenic and can be used for the development of enzymelinked immunosorbent assay systems. </p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>вирус Марбург (Marburgvirus</kwd><kwd>MARV)</kwd><kwd>гликопротеин (GP)</kwd><kwd>нуклеопротеин (NP)</kwd><kwd>матриксный белок (VP40)</kwd><kwd>рекомбинантные белки</kwd><kwd>серологическая диагностика</kwd></kwd-group><kwd-group xml:lang="en"><kwd>Marburg virus (MARV)</kwd><kwd>glycoprotein (GP)</kwd><kwd>nucleoprotein (NP)</kwd><kwd>matrix protein (VP40)</kwd><kwd>recombinant proteins</kwd><kwd>serological diagnostics</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Авторы выражают благодарность доктору биологических наук А.А. Чепурнову за предоставление материалов.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Телесманич Н.Р., Микашинович З.И., Ломаковский Н.С., Лосева Т.Д., Чайка С.О. Биохимия вируса Эбола и молекулярные аспекты биологической защиты. Журнал фундаментальной медицины и биологии. 2015; 3:28–34.</mixed-citation><mixed-citation xml:lang="en">Telesmanich N.R., Mikashinovich Z.I., Lomakovsky N.S., Loseva T.D., Chaika S.O. [Biochemistry of the Ebola virus and mo- lecular aspects of biological defense]. Zhurnal Fundamental’noj Meditsiny i Biologii [Journal of Fundamental Medicine and Biology]. 2015; 3:28–34.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Qiu X., Wong G., Audet J., Cutts T., Niu Y., Booth S., Kobinger G.P. Establishment and characterization of a lethal mouse model for the Angola strain of Marburg virus. J. Virol. 2014; 88(21):12703–14. DOI: 10.1128/JVI.01643-14.</mixed-citation><mixed-citation xml:lang="en">Qiu X., Wong G., Audet J., Cutts T., Niu Y., Booth S., Kobinger G.P. Establishment and characterization of a lethal mouse model for the Angola strain of Marburg virus. J. Virol. 2014; 88(21):12703–14. DOI: 10.1128/JVI.01643-14.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Vetter P., Fischer W.A. 2nd, Schibler M., Jacobs M., Bausch D.G., Kaiser L. Ebola Virus shedding and transmission: review of current evidence. J. Infect. Dis. 2016; 214(suppl 3):S177–S184. DOI: 10.1093/infdis/jiw254.</mixed-citation><mixed-citation xml:lang="en">Vetter P., Fischer W.A. 2nd, Schibler M., Jacobs M., Bausch D.G., Kaiser L. Ebola Virus shedding and transmission: review of current evidence. J. Infect. Dis. 2016; 214(suppl 3):S177–S184. DOI: 10.1093/infdis/jiw254.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Pawęska J.T., Jansen van Vuren P., Kemp A., Storm N., Grobbelaar A.A., Wiley M.R., Palacios G., Markotter W. Marburg virus infection in Egyptian rousette bats, South Africa, 2013– 2014. Emerg. Infect. Dis. 2018; 24(6):1134–7. DOI: 10.3201/eid2406.172165.</mixed-citation><mixed-citation xml:lang="en">Pawęska J.T., Jansen van Vuren P., Kemp A., Storm N., Grobbelaar A.A., Wiley M.R., Palacios G., Markotter W. Marburg virus infection in Egyptian rousette bats, South Africa, 2013– 2014. Emerg. Infect. Dis. 2018; 24(6):1134–7. DOI: 10.3201/eid2406.172165.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Brangel P., Sobarzo A., Parolo C., Miller B.S., Howes P.D., Gelkop S., Lutwama J.J., Dye J.M., McKendry R.A., Lobel L., Stevens M.M. A serological point-of-care test for the detection of IgG antibodies against Ebola virus in human survivors. ACS Nano. 2018; 12(1):63–73. DOI: 10.1021/acsnano.7b07021.</mixed-citation><mixed-citation xml:lang="en">Brangel P., Sobarzo A., Parolo C., Miller B.S., Howes P.D., Gelkop S., Lutwama J.J., Dye J.M., McKendry R.A., Lobel L., Stevens M.M. A serological point-of-care test for the detection of IgG antibodies against Ebola virus in human survivors. ACS Nano. 2018; 12(1):63–73. DOI: 10.1021/acsnano.7b07021.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Программное обеспечение Snapgene. [Электронный ресурс]. URL: https://www.snapgene.com (дата обращения 17.05.2020).</mixed-citation><mixed-citation xml:lang="en">Snapgene software. (Cited 17 May 2020). [Internet]. Available from: https://www.snapgene.com/.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Волкова Н.В., Пьянков О.В., Иванова А.В., Исаева А.А., Зыбкина А.В., Казачинская Е.И., Щербаков Д.Н. Прототип ДНКвакцины против вируса Марбург. Бюллетень экспериментальной биологии и медицины. 2020; 170(10):487–91. DOI: 10.47056/03659615-2020-170-10-487-491.</mixed-citation><mixed-citation xml:lang="en">Volkova N.V., Pyankov O.V., Ivanova A.V., Isaeva A.A., Zybkina A.V., Kazachinskaya E.I., Shcherbakov D.N. [A prototype of a DNA vaccine against Marburg virus]. Bulleten’ Eksperimental’noj Biologii i Meditsiny [Bulletin of Experimental Biology and Medicine]. 2020; 170(10):487–91. DOI: 10.47056/0365-9615-2020-170-10-487-491.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Полежаева О.А., Щербаков Д.Н. Разработка панели псевдовирусных частиц, экспонирующих гликопротеин вируса Марбург. Международный научно-исследовательский журнал. 2017; 8–2:27–30. DOI: 10.23670/IRJ.2017.62.018.</mixed-citation><mixed-citation xml:lang="en">Polezhaeva O.A., Shcherbakov D.N. [Development of a panel of pseudovirus particles exhibiting the glycoprotein of the Marburg virus]. Mezhdunarodny Nauchno-Issledovatel’sky Zhurnal [International Research Journal]. 2017; 8–2:27–30. DOI: 10.23670/IRJ.2017.62.018.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Hodek P., Trefil P., Simunek J., Hudecek J., Stiborova M. Optimized protocol of chicken antibody (IgY) purification providing electrophoretically homogenous preparations. Int. J. Electrochem. Sci. 2013; 8:113–124.</mixed-citation><mixed-citation xml:lang="en">Hodek P., Trefil P., Simunek J., Hudecek J., Stiborova M. Optimized protocol of chicken antibody (IgY) purification providing electrophoretically homogenous preparations. Int. J. Electrochem. Sci. 2013; 8:113–124.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Sobarzo A., Perelman E., Groseth A., Dolnik O., Becker S., Lutwama J.J., Dye J.M., Yavelsky V., Lobel L., Marks R.S. Profiling the native specific human humoral immune response to Sudan Ebola virus strain Gulu by chemiluminescence enzyme-linked immunosorbent assay. Clin. Vaccine Immunol. 2012; 19(11):1844–52. DOI: 10.1128/CVI.00363-12.</mixed-citation><mixed-citation xml:lang="en">Sobarzo A., Perelman E., Groseth A., Dolnik O., Becker S., Lutwama J.J., Dye J.M., Yavelsky V., Lobel L., Marks R.S. Profiling the native specific human humoral immune response to Sudan Ebola virus strain Gulu by chemiluminescence enzyme-linked immuno- sorbent assay. Clin. Vaccine Immunol. 2012; 19(11):1844–52. DOI: 10.1128/CVI.00363-12.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Kamata T., Natesan M., Warfield K., Aman M.J., Ulrich R.G. Determination of specific antibody responses to the six species of Ebola and Marburg viruses by multiplexed protein microarrays. Clin. Vaccine Immunol. 2014; 21(12):1605–12. DOI: 10.1128/CVI.00484-14.</mixed-citation><mixed-citation xml:lang="en">Kamata T., Natesan M., Warfield K., Aman M.J., Ulrich R.G. Determination of specific antibody responses to the six spe- cies of Ebola and Marburg viruses by multiplexed protein microar- rays. Clin. Vaccine Immunol. 2014; 21(12):1605–12. DOI: 10.1128/CVI.00484-14.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Thermo Fisher Scientific. [Электронный ресурс]. URL: https://www.thermofisher.com/ru/en/home/life-science/cloning/ gene-synthesis/geneart-gene-synthesis/geneoptimizer.html (дата обращения 22.06.2020).</mixed-citation><mixed-citation xml:lang="en">Thermo Fisher Scientific. (Cited 22 June 2020). [Internet]. Available from: https://www.thermofisher.com/ru/en/home/life-science/cloning/gene-synthesis/geneart-gene-synthesis/geneoptimizer.html/.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
